Literature DB >> 3065927

Clinical and bacteriological effects of therapy of urinary tract infection in primary health care: relation to in vitro sensitivity testing.

S Ferry1, L G Burman, S E Holm.   

Abstract

17 primary health care (PHC) centres participated in a 1-month evaluation of a county urinary tract infection (UTI) management program. A total of 302 patients contributing 355 episodes, dominated by female (93%), lower symptomatic (75%) and Escherichia coli (74%) episodes were studied. In therapeutic failure gram-negative bacteria other than E. coli showed an increased prevalence whereas Staphylococcus saprophyticus was not found. The general pattern of drug resistance was little influenced by UTI history and the mean pretherapy prevalence of resistance to the 7 antibacterial agents studied was low (7%). Drug resistance was increased in failure (mean 24%) also for agents not used for therapy (sulphonamides and nitrofurantoin) but not in early or repeated recurrence. UTI symptoms were eradicated in only two-thirds of bacteriologically cured episodes but in one-third of the failures at the posttreatment control. On average, therapy resulted in 8% bacteriological failure and 12% early recurrence. The bacteriological cure rate was the same irrespective of whether the infecting bacteria were classified as sensitive or resistant in vitro to the drug given. Thus, sensitivity testing of isolates is rarely needed in sporadic or recurrent UTI in PHC but may be relevant in failure. In order to be of prognostic value in uncomplicated UTI high-level breakpoints focusing more on peak urinary drug concentrations need to be studied.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3065927     DOI: 10.3109/00365548809032503

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  8 in total

1.  Wagging the dog: antibiotic use and the emergence of resistance.

Authors:  E Lautenbach; N O Fishman
Journal:  J Gen Intern Med       Date:  1999-10       Impact factor: 5.128

2.  Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: the LUTIW project.

Authors:  Sven A Ferry; Stig E Holm; Hans Stenlund; Rolf Lundholm; Tor J Monsen
Journal:  Scand J Prim Health Care       Date:  2007-03       Impact factor: 2.581

3.  In vitro and in vivo effects of soluble, monovalent globotriose on bacterial attachment and colonization.

Authors:  James L Leach; Stacey A Garber; Andrea A Marcon; Pedro A Prieto
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

4.  Staphylococcus saprophyticus urinary tract infections: epidemiological data from Western Australia.

Authors:  P F Schneider; T V Riley
Journal:  Eur J Epidemiol       Date:  1996-02       Impact factor: 8.082

5.  Increased treatment failure after 3-days' courses of nitrofurantoin and trimethoprim for urinary tract infections in women: a population-based retrospective cohort study using the PHARMO database.

Authors:  Wim G Goettsch; Rob Janknegt; Ron M C Herings
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

6.  Antibiotic resistance of urinary tract pathogens and rationale for empirical intravenous therapy.

Authors:  Maria Haller; Matthias Brandis; Reinhard Berner
Journal:  Pediatr Nephrol       Date:  2004-06-18       Impact factor: 3.714

7.  Treating acute cystitis with biodegradable micelle-encapsulated quercetin.

Authors:  Bi Lan Wang; Xiang Gao; Ke Men; Jinfeng Qiu; Bowen Yang; Ma Ling Gou; Mei Juan Huang; Ning Huang; Zhi Yong Qian; Xia Zhao; Yu Quan Wei
Journal:  Int J Nanomedicine       Date:  2012-05-08

8.  Comparison of Escherichia coli strains recovered from human cystitis and pyelonephritis infections in transurethrally challenged mice.

Authors:  D E Johnson; C V Lockatell; R G Russell; J R Hebel; M D Island; A Stapleton; W E Stamm; J W Warren
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.